Girentuximab (G250) 是一种嵌合单克隆抗体，可与碳酸酐酶 IX (CAIX) 结合，碳酸酐酶 IX 是一种在透明细胞肾细胞癌 (ccRCC) 中广泛表达的细胞表面糖蛋白。
| 生物活性 | Girentuximab (G250) is a chimeric monoclonal antibody that bindscarbonic anhydraseIX (CAIX), a cell surfaceglycoproteinubiquitously expressed in clear cell renal cell carcinoma (ccRCC)[1]. |
体外研究
(In Vitro) | Girentuximab is an IgG1 κ light chain chimeric version of a murine monoclonal antibody (mAb) and recognizes the antigen CAIX[1].
|
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
